THC is currently illegal under federal law. Whether the federal government should regulate state marijuana programs continues to be disputed on the national stage. With the rise of vaping-related lung injuries and CBD oil flooding the market, the call for a reform of federal drug scheduling laws are quickly moving to the top of the regulatory agenda.

• Analyzing the recent scheduling change of CBD in the wake of the DEA’s schedule I classification of the epilepsy medication Epidiolex
• Reviewing the status of hemp, marijuana, and other cannabinoids under current federal law
  • Distinguishing “hemp-derived” from “marijuana-derived”
• Navigating the legal pathways for bringing cannabinoids to market
• Considering the evolving development of state cannabis laws
• Understanding the emergence of cannabidiol and its future in the controlled substance arena
• Complying with state storage and record keeping laws